Cefepime/Sulbactam — A New Innovative Antibiotic for In-Hospital Treatment of Severe Infections and the Implementation of Carbapenem-Replacement Strategy to Contain Antibiotic Resistance
- 25 June 2021
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 66 (3-4), 82-98
- https://doi.org/10.37489/0235-2990-2021-66-3-4-82-98
Abstract
Cefepime/sulbactam is a combined antibiotic consisting of the 4 th generation cephalosporin cefepime and the beta-lactamase inhibitor sulbactam in 1:1 ratio. Cefepime/sulbactam antibiotic was developed in Russia in 2006, it had passed preclinical and clinical studies, was approved for medical use, and has been produced in Russia since 2019. Cefepime has a wide spectrum of antimicrobial activity against gram-positive and gram-negative microorganisms, sulbactam adds two clinically important pathogens to the antimicrobial spectrum of cefepime —Acinetobacter baumanniiandBacteroides fragilis. In addition, sulbactam protects cefepime from hydrolysis by class A broad- and extended-spectrum beta-lactamases, and cefepime itself is stable against class C chromosomal beta-lactamases and partially stable to OXA-type class D carbapenemases.In vitrostudies have shown that most clinical strains of ESBL-producingKlebsiella pneumoniae,Escherichia coli,Proteusspp. are sensitive to cefepime/sulbactam, as well as some strains ofK.pneumoniaeandA.baumanniithat are resistant to carbapenems as a result of the production of class D carbapenemases. The efficacy and safety of cefepime/sulbactam have been determined in three clinical studies. Clinical and bacteriological efficacy of the drug was 97.9% and 97.6% in patients with acute community-acquired pyelonephritis. In the MAXI-19 multicenter study, the clinical efficacy of cefepime/sulbactam in patients with intra-abdominal infections, nosocomial pneumonia, and ventilator-associated pneumonia was 78.4, 90.3, and 80.7%, respectively. A comparative study examined the efficacy of cefepime/sulbactam and carbapenems in severe nosocomial infections (84% of patients had sepsis or septic shock). Clinical efficacy of cefepime/sulbactam and carbapenems was high and did not significantly differ (71% vs. 62%), as well as the bacteriological efficacy — 87% vs. 73%, while typical hospital pathogens characterized by MDR or XDR were identified in the majority of patients (most often —K.pneumoniae,A.baumannii,E.coli). During treatment with carbapenems, carbapenem-resistant bacteria were detected significantly more often (74.5%, most oftenA.baumannii— 44.7%,K.pneumoniae— 38.3%), compared to cefepime/sulbactam (20.0%,P.aeruginosaandK.pneumoniae, both at 15.5%), P=0.0001. The risk of superinfection was also significantly higher with carbapenems than with cefepime/sulbactam (53.3% vs. 22.2%, P=0.001). For severe infections, cefepime/sulbactam was administered at a dose of 4 g (2 g + 2 g) every 12 hours or 2 g (1 g + 1 g) every 8 hours. Currently, cefepime/sulbactam should be considered as a reliable option for the treatment of severe infections in the hospital as a carbapenem-replacement strategy to reduce the risks of selection of carbapenem-resistant gram-negative bacteria.Keywords
This publication has 35 references indexed in Scilit:
- In vitroeffects of sulbactam combinations with different antibiotic groups against clinicalAcinetobacter baumanniiisolatesJournal of Chemotherapy, 2012
- Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic StewardshipClinical Infectious Diseases, 2009
- Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.International Journal of Antimicrobial Agents, 2006
- Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinationsBiochemical Pharmacology, 2006
- In vitro activities of β-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteriaInternational Journal of Antimicrobial Agents, 2004
- In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniaeDiagnostic Microbiology and Infectious Disease, 2004
- Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum β-Lactamase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2001
- Bactericidal activity of three β-lactams alone or in combination with a β-lactamase inhibitor and two aminoglycosides against Klebsiella pneumoniae harboring extended-spectrum β-lactamasesClinical Microbiology & Infection, 1998
- CefepimeDrugs, 1994